7 hasil untuk "Emanuela Ferraro"
Menampilkan 1–7 · 0,71 detik · RSS
-
Artikel Jurnal
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
Abstract The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize…
-
Artikel Jurnal Teks lengkap
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions
Immunotherapy has become a cornerstone of cancer treatment in both the early and advanced setting in recent years, leading to the achievement of substantial and durable responses with an excellent safety profile across different tumor types. This demonstrates the high potential of engaging the…
-
Artikel Jurnal
Serotype 3 invasive pneumococcal disease in Tuscany across the eras of conjugate vaccines (2005–2024) and anthropic-driven respiratory virus fluctuations
Serotype 3 Streptococcus pneumoniae (ser3) has emerged as a leading cause of invasive pneumococcal disease (IPD) despite targeted vaccination efforts. Preliminary evidence reported a differential impact of anti-ser3-pneumococcal-conjugate-vaccines (PCVser3) on different clinical presentations of…
-
Artikel Jurnal
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
Resistance to HER2 inhibition in HER2- amplified breast cancer is common in the metastatic setting and the underlying molecular mechanisms remain unknown. Here, the authors, perform genomic profiling of 733 HER2-amplified breast cancers and propose genetic activation of MAPK as a resistance…
-
Artikel Jurnal
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
Abstract The addition of pertuzumab (P) to trastuzumab (H) and neoadjuvant chemotherapy (NAC) has decreased the risk of distant recurrence in early stage HER2-positive breast cancer. The incidence of brain metastases (BM) in patients who achieved pathological complete response (pCR) versus those…
-
Artikel Jurnal
Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy
Abstract Circulating tumor DNA (ctDNA) has potential as a prognostic factor for predicting relapse in high-risk breast cancer (BC). This study investigates the utility of ctDNA assessment using a tumor-informed assay, in patients with high-risk BC treated with neoadjuvant chemotherapy (NAC). Thirty…
-
Artikel Jurnal
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Background: Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the neoadjuvant, adjuvant, and metastatic settings, including for parenchymal brain metastases, their efficacy for patients with LM has…